OrbiMed Advisors NSPR Position
ActiveOrbiMed Advisors increased their position in InspireMD, Inc. (NSPR) in Q4 2025, holding $5.6M worth of shares across 3,133,405 shares.
The position was first reported in Q2 2023 and has been tracked across 11 quarterly 13F filings.
About InspireMD, Inc.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Full company profile →Short Interest
0.1%
0.8 days to cover
OrbiMed Advisors NSPR Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 3,133,405 | +1,000,000 | $5.6M |
| Q3 2025 | Held | 2,133,405 | — | $5.1M |
| Q2 2025 | Held | 2,133,405 | — | $4.8M |
| Q1 2025 | Held | 2,133,405 | — | $5.7M |
| Q4 2024 | Held | 2,133,405 | — | $5.6M |
| Q3 2024 | Held | 2,133,405 | — | $5.7M |
| Q2 2024 | Held | 2,133,405 | — | $5.3M |
| Q1 2024 | Held | 2,133,405 | — | $5.1M |
| Q4 2023 | Increased | 2,133,405 | +273,000 | $6.0M |
| Q3 2023 | Held | 1,860,405 | — | $6.1M |
| Q2 2023 | New | 1,860,405 | +1,860,405 | $4.7M |
Frequently Asked Questions
Does OrbiMed Advisors own NSPR?
Yes. As of Q4 2025, OrbiMed Advisors holds 3,133,405 shares of InspireMD, Inc. (NSPR) valued at $5.6M. This data comes from their SEC 13F filing.
How many hedge funds own NSPR?
1 specialist biotech hedge fund currently holds NSPR. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy NSPR?
OrbiMed Advisors's position in NSPR was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's NSPR position increasing or decreasing?
OrbiMed Advisors increased their NSPR position in the most recent quarter, adding 1,000,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NSPRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →